ZLAB logo

ZLAB
Zai Lab Ltd

1,231
Mkt Cap
$2.36B
Volume
228,260.00
52W High
$44.34
52W Low
$15.96
PE Ratio
-13.05
ZLAB Fundamentals
Price
$20.98
Prev Close
$21.22
Open
$21.22
50D MA
$20.25
Beta
1.13
Avg. Volume
839,019.35
EPS (Annual)
-$1.61
P/B
3.24
Rev/Employee
$258,617.15
$1,366.81
Loading...
Loading...
News
all
press releases
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call
Zai Lab (NASDAQ:ZLAB) hosted an investor call tied to the 2026 American Association for Cancer Research (AACR) meeting to highlight new data for its DLL3-targeted antibody-drug conjugate (ADC...
MarketBeat·10d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Trading Down 5.2% - Here's What Happened
Zai Lab (NASDAQ:ZLAB) Shares Down 5.2% - What's Next...
MarketBeat·13d ago
News Placeholder
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2026 financial results and provide recent corporate updates on May 7, 2026, before the opening of U.S...
Business Wire·14d ago
News Placeholder
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31R Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the companys internally developed IL-13/IL-31R bispecific antibody may lead...
Business Wire·18d ago
News Placeholder
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and...
Business Wire·18d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading Volume - Time to Buy?
Zai Lab (NASDAQ:ZLAB) Sees Large Volume Increase - Here's What Happened...
MarketBeat·18d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 2,653 Shares
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 2,653 shares of the firm's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of...
MarketBeat·27d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) Insider Sells $61,697.65 in Stock
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) insider Joshua Smiley sold 3,017 shares of the business's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $20.45, for a total value of $61,697.65. Following the completion of the sale, the...
MarketBeat·27d ago
News Placeholder
Zai Lab (NASDAQ:ZLAB) CEO Sells $54,253.85 in Stock
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 2,653 shares of the business's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85. Following the transaction, the chief executive...
MarketBeat·27d ago
<
1
2
...
>

Latest ZLAB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.